BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+46.01%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$7.07B
AUM Growth
+$7.07B
(+37%)
Cap. Flow
+$60.6M
Cap. Flow
% of AUM
0.86%
Top 10 Holdings %
Top 10 Hldgs %
40.22%
Holding
231
New
17
Increased
84
Reduced
52
Closed
23
Top Buys
| 1 |
Edwards Lifesciences
EW
|
$38.5M |
| 2 |
Generation Bio
GBIO
|
$30.2M |
| 3 |
Stryker
SYK
|
$27.2M |
| 4 |
Insulet
PODD
|
$25.1M |
| 5 |
Bristol-Myers Squibb
BMY
|
$23.9M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$84.3M |
| 2 |
Moderna
MRNA
|
$38.9M |
| 3 |
Illumina
ILMN
|
$38.1M |
| 4 |
Intuitive Surgical
ISRG
|
$36.5M |
| 5 |
MacroGenics
MGNX
|
$31.2M |
Sector Composition
| 1 | Healthcare | 96.05% |
| 2 | Industrials | 0.58% |
| 3 | Technology | 0.42% |
| 4 | Communication Services | 0.29% |
| 5 | Financials | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ionis Pharmaceuticals
IONS
$6.79B
| $486M | 6.88% |
8,249,873
-129,769
| -2% | -$7.65M |
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $392M | 5.54% |
3,210,900
-48,574
| -1% | -$5.93M |
|
3
Incyte
INCY
$16.5B
| $342M | 4.84% |
3,292,600
-31,400
| -0.9% | -$3.26M |
|
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $285M | 4.04% |
982,600
-290,489
| -23% | -$84.3M |
|
5
Esperion Therapeutics
ESPR
$448M
| $272M | 3.85% |
5,303,135
+265,245
| +5% | +$13.6M |
|
6
Alnylam Pharmaceuticals
ALNY
$58.5B
| $238M | 3.37% |
1,610,065
-165,199
| -9% | -$24.5M |
|
7
Agios Pharmaceuticals
AGIO
$2.19B
| $215M | 3.05% |
4,023,573
+118,129
| +3% | +$6.32M |
|
8
argenx
ARGX
$43.6B
| $215M | 3.04% |
954,016
-20,488
| -2% | -$4.61M |
|
|
9
Moderna
MRNA
$9.37B
| $215M | 3.04% |
3,344,950
-605,231
| -15% | -$38.9M |
|
10
Halozyme
HALO
$8.56B
| $180M | 2.55% |
6,730,552
-933,404
| -12% | -$25M |
|
|
ALXN
11
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $159M | 2.24% |
1,412,828
+81,500
| +6% | +$9.15M |
|
|
12
MacroGenics
MGNX
$112M
| $140M | 1.98% |
5,002,116
-1,117,034
| -18% | -$31.2M |
|
13
Abbott
ABT
$231B
| $117M | 1.66% |
1,284,272
| – | – |
|
|
MYOK
14
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $117M | 1.65% |
1,208,313
-103,400
| -8% | -$9.99M |
|
|
ITCI
15
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $97M | 1.37% |
3,779,919
+48,100
| +1% | +$1.23M |
|
|
MYOV
16
DELISTED
Myovant Sciences Ltd.
MYOV
| $95.8M | 1.36% |
4,647,000
-168,109
| -3% | -$3.47M |
|
|
RDUS
17
DELISTED
Radius Health, Inc.
RDUS
| $95.5M | 1.35% |
7,007,385
+24,000
| +0.3% | +$327K |
|
|
18
Bristol-Myers Squibb
BMY
$96B
| $94.8M | 1.34% |
1,612,112
+406,640
| +34% | +$23.9M |
|
19
Humana
HUM
$36.5B
| $91.4M | 1.29% |
235,640
+37,522
| +19% | +$14.5M |
|
20
UnitedHealth
UNH
$281B
| $90.4M | 1.28% |
306,636
-9,572
| -3% | -$2.82M |
|
21
Medtronic
MDT
$119B
| $89.6M | 1.27% |
977,523
+32,207
| +3% | +$2.95M |
|
|
22
Intuitive Surgical
ISRG
$170B
| $89M | 1.26% |
156,233
-64,138
| -29% | -$36.5M |
|
23
Nektar Therapeutics
NKTR
$568M
| $81.9M | 1.16% |
3,535,013
+50,300
| +1% | +$1.16M |
|
24
Elevance Health
ELV
$71.8B
| $81.5M | 1.15% |
310,025
-55,578
| -15% | -$14.6M |
|
25
Danaher
DHR
$147B
| $79.9M | 1.13% |
451,633
+106,152
| +31% | +$18.8M |
|